A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis

1. Quantify how much PD-0332334 is removed from the blood with hemodialysis
2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments.
3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.

Assess the elimination of PD-0332334 from the blood with hemodialysis

Inclusion Criteria:

• Patients receiving regular hemodialysis
• Male or female patients 18 to 65 years

Exclusion Criteria:

• Severe heart failure
• Renal transplant or renal allograft
• Illicit drug use (with the exception of prescribed sedatives)